What is the official website of MedAdvisor Solutions US ?

The official website of MedAdvisor Solutions US is https://www.medadvisorsolutions.com/.

What is MedAdvisor Solutions US's cybersecurity risk score?

MedAdvisor Solutions US has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MedAdvisor Solutions US experienced?

According to Rankiteo, MedAdvisor Solutions US currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MedAdvisor Solutions US been affected by any supply chain cyber incidents ?

According to Rankiteo, MedAdvisor Solutions US has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MedAdvisor Solutions US have SOC 2 Type 1 certification ?

According to Rankiteo, MedAdvisor Solutions US is not certified under SOC 2 Type 1.

Does MedAdvisor Solutions US have SOC 2 Type 2 certification ?

According to Rankiteo, MedAdvisor Solutions US does not hold a SOC 2 Type 2 certification.

Does MedAdvisor Solutions US comply with GDPR ?

According to Rankiteo, MedAdvisor Solutions US is not listed as GDPR compliant.

Does MedAdvisor Solutions US have PCI DSS certification ?

According to Rankiteo, MedAdvisor Solutions US does not currently maintain PCI DSS compliance.

Does MedAdvisor Solutions US comply with HIPAA ?

According to Rankiteo, MedAdvisor Solutions US is not compliant with HIPAA regulations.

Does MedAdvisor Solutions US have ISO 27001 certification ?

According to Rankiteo,MedAdvisor Solutions US is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MedAdvisor Solutions US operate in ?

MedAdvisor Solutions US operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MedAdvisor Solutions US have ?

MedAdvisor Solutions US employs approximately 85 people worldwide.

Does MedAdvisor Solutions US own any subsidiaries ?

MedAdvisor Solutions US presently has no subsidiaries across any sectors.

How many LinkedIn followers does MedAdvisor Solutions US have ?

MedAdvisor Solutions US's official LinkedIn profile has approximately 3,488 followers.

What is the NAICS classification code for MedAdvisor Solutions US ?

MedAdvisor Solutions US is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MedAdvisor Solutions US have a Crunchbase profile ?

No, MedAdvisor Solutions US does not have a profile on Crunchbase.

Does MedAdvisor Solutions US have a LinkedIn profile ?

Yes, MedAdvisor Solutions US maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/medadvisorsolutions-us.

How many cybersecurity incidents has MedAdvisor Solutions US experienced ?

As of July 23, 2026, Rankiteo reports that MedAdvisor Solutions US has not experienced any cybersecurity incidents.

How many peer or competitor companies does MedAdvisor Solutions US have ?

MedAdvisor Solutions US has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSU

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

MedAdvisor Solutions US Vendor Cyber Rating & Cyber Score

medadvisorsolutions.com

Add Your Compliance Badge

MedAdvisor Solutions, formerly Adheris Health, is a global leader in pharma-sponsored and pharmacy-driven patient engagement solutions that provide individualized patient experiences to simplify the patient medication journey. Our omnichannel engagement solutions include health content, digital and non-digital communication tools, rich data and an AI-enabled platform. Our approach complements what pharmacies are already doing to reach patients with valuable resources when and where it’s convenient and effective. The solutions support an array of growth objectives including market development, patient engagement, clinical services expansion, pharmacist workflow support, awareness and adherence program development, and more. MedAdvisor

MSU A.I CyberSecurity Scoring

Scoring History

MSU

MedAdvisor Solutions US CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

MSU Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSU

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MedAdvisor Solutions US in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MedAdvisor Solutions US in 2026.

Incident Types MSU vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MedAdvisor Solutions US in 2026.

Incident History - MSU (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MedAdvisor Solutions US Subsidiaries

MSU

Pharmaceutical Manufacturing

Website: https://www.medadvisorsolutions.com/

Company Size: 201-500 employees

Syneos Health Commercial SolutionsBiotechnology Research

Syneos HealthBiotechnology Research

Syneos Health CommunicationsAdvertising Services

GSW, powered by Syneos HealthAdvertising Services

GENICOS, powered by Syneos HealthAdvertising Services

Addison WhitneyAdvertising Services

Litmus Medical CommunicationsPharmaceutical Manufacturing

Chandler Chicco Agency (CCA)Public Relations and Communications Services

Biosector 2Public Relations and Communications Services

Chamberlain Healthcare Public RelationsPublic Relations and Communications Services

Cadent, powered by Syneos HealthPharmaceutical Manufacturing

InCommon, a division of CadentPharmaceutical Manufacturing

InCight, a division of CadentPharmaceutical Manufacturing

Syneos Health Learning SolutionsPharmaceutical Manufacturing

Loading…

MedAdvisor Solutions US Similar Companies

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Loading…

NEWS

MedAdvisor Solutions US CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 17, 2024 08:00 AM

Mindsprint announces strategic partnership with MedAdvisor Solutions to transform patient medication management

PRNewswire/ -- Mindsprint, a leading global provider of software products, digital services, and business processes, announced a strategic...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-61246

SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60455

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60439

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60373

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60372

SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 9.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H).

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…